logo
Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?

Register
    

Rexahn Pharmaceuticals (RNN) Continues to Spike on Potential Cancer Pill, Roth Upgrade

By  +Follow January 13, 2014 10:17AM
Share:
Tickers Mentioned:

Shares in Rexahn Pharmaceuticals (RNN) jumped nearly 40 percent on Monday, continuing a bull-run that has the stock up over 150 percent since Thursday and over 265 percent in the last month on a promising potential cancer treatment and the initiation of relatively bullish coverage from Roth Capital Markets analysts.

RNN’s RX-3117 Could be Alternative for Eli Lilly’s Gemzar

Driving the current growth-spurt is the announcement of the initation of Phase 1b to study the safety and efficacy of RX-3117, Rexahn’s lead drug candidate, in cancer patients with solid tumors. The hype surrounding RX-3117 is considerable given that it has to potential to function as an oral to Eli Lilly’s (LLY) Gemzar.

"The initiation of this Phase I clinical trial of RX-3117 represents an important milestone for Rexahn," said CEO Peter D. Suzdak, Ph.D. "This compound is exciting to work with, as it has a unique profile with demonstrated activity against gemcitabine-resistant human cancer cells. We were pleased to see reduced side effect liability and oral bioavailability in cancer patients in our initial exploratory Phase I clinical trial conducted in Europe, and we believe that RX-3117 may represent a significant advancement in the treatment of cancer patients with solid tumors."

Gemzar is an injectable drug that results in resistance for 1 out of 4 patients, making an alternative that functions in pill form one with considerable commercial potential.

Analyst Seems Convinced

Also helping boost shares over the past few days was the news from Thursday that Roth Capital Markets’ Joe Pantiginis had initiated coverage on the stock at a “buy” rating with a price target of $3, still nearly double the current share price even after the spike in price.

Along with the considerable potential for RX-3117, the company boasts nearly $15 million in cash as well as over $5 million in new funding, giving it enough money to carry it for two years.

 

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions.


Liked What You Read? Join Equities.com as a contributor and get eyeballs on your content FOR FREE!

Results for rnn
Market News
29 Aug 14 11:44:41
$RNN: Rexahn Pharmaceuticals Short Interest Down 2.8% in August (RNN) http://t.co/X4zADdsifp http://t.co/kXaqd36L4D
Charles
29 Aug 14 11:29:05
$RNN the saddest bag i've held is my own poop on a long walk. but aside from that, yes, this is one sad sack.
lavina
28 Aug 14 05:37:49
RT @micheleciani: #biotech #buy #stocks $MACK $OXGN $CPHI $OREX $LPDX $MNOV $AEZS $RNN $CYTR $SGYP $AGEN $CPRX and others http://t.co/rYBtM…
Owl Trader
28 Aug 14 05:07:24
Easy Money $XXII $JRJC $VII $ISNS $DLGY $RNN $CYTK http://t.co/Lbaq68Ohd1
Michele Ciani
28 Aug 14 04:50:19
#biotech #buy #stocks $MACK $OXGN $CPHI $OREX $LPDX $MNOV $AEZS $RNN $CYTR $SGYP $AGEN $CPRX and others http://t.co/rYBtM6Xeuj
Sleek Money
28 Aug 14 01:35:34
Short Interest in Rexahn Pharmaceuticals Decreases By 2.8% $RNN http://t.co/iXh89Y0VqP
Market Updates
27 Aug 14 23:44:22
$RNN: Rexahn Announces Additional Data from Preclinical Studies of RX-3117 http://t.co/pHSrwZy896 http://t.co/39cIpCMHaF
US Banking News
27 Aug 14 23:35:40
Rexahn Pharmaceuticals Short Interest Down 2.8% in August $RNN http://t.co/RwcQChLmpn
Ticker Report
27 Aug 14 23:28:00
Rexahn Pharmaceuticals Short Interest Down 2.8% in August $RNN http://t.co/V311m034II
WallStreet Pennies
27 Aug 14 06:05:10
Dollar$OnPennies: $RNN Gallery View http://t.co/bTpqC69E0Z
BreakoutStreetPicks
26 Aug 14 21:02:04
Follow me on StockTwits @BreakoutStreetPicks ... $MSTX $PVCT $RNN $INFN $GIB $WATT $ZPIN
StockSpotter
26 Aug 14 08:33:43
$RNN up 1.4% to 0.72 bullish setup alert #stocks #options #markets http://t.co/sVHICKF2Up
Stocks in News
25 Aug 14 12:44:39
$RNN: Rexahn Pharmaceuticals: An Undervalued Oncology Play With Risk Diversification http://t.co/DPH3xkdgaz http://t.co/WtMk12WmKs
Biotex
25 Aug 14 12:25:47
want to play $RNN but this one is just...
Andrés De Sousa E.
25 Aug 14 03:54:19
"@WallStArtist: $RNN Bullish Continuation wedge Confirmed, Correction to last post. http://t.co/wduh8gk3IS"
Paul McIntosh
25 Aug 14 03:53:37
$RNN Bullish Continuation wedge Confirmed, Correction to last post. http://t.co/DshrpcJtrU
Paul McIntosh
25 Aug 14 03:51:31
$RNN Could Finally See Upside on Bullish Continuation Wedge Confirmation http://t.co/2BEG10KH9T
Jet Life PennyStock$
25 Aug 14 00:23:11
Dollar$OnPennies: $RNN Gallery View http://t.co/8QAPhTbzAW
Market Updates
23 Aug 14 15:44:21
$RNN: Rexahn files $150M mixed securities shelf http://t.co/59BiYUq83k http://t.co/4Nei9UIpNT
MarketBoss_2020
23 Aug 14 14:54:44
$RNN ~ Krill123~you may as well text yourself with these comments! No One is listening ~Move On~find a stock u like & post informatively
				
				
By  +Follow January 13, 2014 10:17AM
Share:

Comments

 

blog comments powered by Disqus

About us

Equities.com is the most advanced interactive online social ecosystem for the financial industry, serving as a resource center and next-generation communication platform that connects self-directed investors with public issuers, market experts, and professional service providers and vendors. Registered members can leverage our exclusive proprietary research tools such as the Small-Cap Stars, which outperformed 90% of all small-cap mutual funds, and robust do-it-yourself E.V.A. research reports. The Equities.com Issuer Dashboard is the ideal tool to communicate and manage investor awareness campaigns to the investment community, as well as to access valuable resources to help your company grow.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.